Elekta AB
EJXB
Company Profile
Business description
Sweden-based Elekta develops, manufactures, and distributes treatment planning systems for neurosurgery and radiotherapy, including stereotactic radiosurgery and brachytherapy. The company has an installed base of more than 7,300 linear accelerators, Gamma Knife and Unity platforms, as well as brachytherapy installations. The company's sales are evenly distributed across geographies, with North and South America accounting for 29%; Europe, the Middle East, and Africa accounting for 37%; and the Asia-Pacific contributing the remainder.
Contact
Hagaplan 4
Box 7593
Stockholm11368
SWET: +46 858725400
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
30 April 2027
Employees
4,353
Stocks News & Analysis
stocks
Wide moat share remains cheap despite rising costs
Higher costs weigh on profits but stronger sales trends support long term outlook.
stocks
Fair value upgrade for ASX listed fast food chain
Earnings beat lifts forecasts but long term growth questions remain.
stocks
Going into earnings, is Nvidia stock a buy, a sell, or fairly valued?
We’re expecting another beat-and-raise quarter, while watching the roadmap and discussions of its financing and partnership deals.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,374.90 | 50.40 | 0.54% |
| CAC 40 | 8,439.20 | 13.81 | -0.16% |
| DAX 40 | 26,266.14 | 159.54 | 0.61% |
| Dow JONES (US) | 53,476.21 | 59.05 | 0.11% |
| FTSE 100 | 10,886.16 | 31.84 | 0.29% |
| HKSE | 25,511.10 | 6.23 | -0.02% |
| NASDAQ | 26,101.36 | 121.17 | 0.47% |
| Nikkei 225 | 65,856.43 | 328.34 | 0.50% |
| NZX 50 Index | 13,992.72 | 110.84 | 0.80% |
| S&P 500 | 7,665.64 | 12.78 | 0.17% |
| S&P/ASX 200 | 9,164.60 | 54.30 | 0.60% |
| SSE Composite Index | 3,889.44 | 7.44 | 0.19% |